Neuland Labs Peptide Manufacturing Module Operational

Neuland Laboratories has announced the operational commencement of its first commercial peptide manufacturing module, significantly expanding its capacity. This module offers 7000L reactor capacity, including both solid-phase (SPPS) and liquid-phase (LPPS) synthesis capabilities, along with DAC columns and lyophilisers. The company is accelerating expansion due to rising customer demand, with foundational infrastructure for a second module already in place. Module two is planned for up to 18,000 L reactor capacity. This expansion supports growing peptide pipelines beyond obesity and metabolic diseases, with oncology emerging as a key area. Neuland's CEO highlighted the goal to meet demand for the next decade, supported by a team of 212 peptide experts. This follows a period of strong growth, with revenues up 116% in recent quarterly results.